Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 496 (miR-496) is a short, non-coding RNA molecule classified as a microRNA that regulates gene expression at the post-transcriptional level by targeting the 3' untranslated regions of specific mRNAs, resulting in mRNA degradation or inhibition of translation[1][3]. It is involved in the regulation of cell proliferation, migration, and differentiation, notably in neural progenitor and cancer cells[2]. In triple negative breast cancer, miR-496 directly targets and downregulates the mRNA of Developmental endothelial locus-1 (Del-1), acting as a tumor suppressor by inhibiting cell proliferation, migration, and invasion[3]. It is consistently downregulated in several types of cancer, including colorectal cancer and triple negative breast cancer, and its expression is associated with better clinical outcomes, suggesting its utility as a prognostic biomarker[3][4][5].
Downregulation of target messenger RNAs (such as Del-1 mRNA in cancer), resulting in translational inhibition or degradation of target mRNAs
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 496 (miR-496).